Cutaneous Lupus Erythematosus (CLE) Clinical Trial
Official title:
A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
| Status | Recruiting |
| Enrollment | 33 |
| Est. completion date | December 2024 |
| Est. primary completion date | December 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Key Inclusion Criteria: - Either fulfill European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE) and/or have biopsy confirmed Cutaneous Lupus Erythematosus (CLE) at any time. - Must have active CLE at screening and Day 1. Individuals with acute CLE (ACLE) must have involvement of 2 distinct body areas. - Cutaneous Lupus Erythematosus Disease Area and Severity Index activity - A (CLASI-A) score (excluding alopecia) of = 8 and CLASI-A erythema score of = 4 during screening and on Day 1. Individuals with SLE must have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of = 4 at screening. - Presence of at least 1 representative lupus skin lesion amenable to punch biopsy and individual willingness to undergo skin punch biopsy at 2 time points. - Must have documented prior intolerance or inadequate response at any time (per investigator judgement) to protocol-specified treatments. - Topical corticosteroids or topical calcineurin inhibitors. - Oral corticosteroids. - Any other nonbiologic standard-of-care therapy, including, but not limited to: chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolate mofetil (MMF), leflunomide, dapsone, or methotrexate (MTX). - Individuals willing to comply with all study visits and assessments. Key Exclusion Criteria: - Individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/or localized acute CLE involving only 1 distinct body area at screening and Day 1. - Have highly active SLE (including but not limited to lupus nephritis, neuropsychiatric SLE, and/or vasculitis). - Presence of active skin conditions other than cutaneous lupus that may interfere with assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-induced lupus). - Meet protocol-specified infection or lab criteria. - Any active infection that is clinically significant (per investigator judgment). - Any history of clinically significant liver disease. - Significant cardiovascular disease. Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
| Country | Name | City | State |
|---|---|---|---|
| Czechia | Kožní ambulance Fialová, s.r.o. | Praha | |
| Czechia | Všeobecná fakultní nemocnice v Praze, Dermatovenerologická klinika | Praha 2 | |
| Germany | Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Allergologie und Venerologie Allergie Centrum | Berlin | |
| Germany | Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Dermatologie | Dresden | |
| Germany | Universitatsklinikum Freiburg Klinik fur Dermatologie und Venerologie | Freiburg | |
| Germany | Universitätsklinikum Leipzig AöR Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Klinische Forschungseinheit (KFE) - Haus 10 | Leipzig | |
| Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
| Spain | Hospital General de Granollers | Granollers | |
| Spain | Hospital Universitario Infanta Leonor | Madrid | |
| Spain | Hospital Universitario de Navarra | Pamplona | |
| United States | Emory University School of Medicine | Atlanta | Georgia |
| United States | University of Colorado, Barbara Davis Center, Center for Clinical Research | Aurora | Colorado |
| United States | OnSite Clinical Solutions, LLC | Charlotte | North Carolina |
| United States | Clinical Research of West Florida, Inc. | Clearwater | Florida |
| United States | Metroplex Clinical Research Center | Dallas | Texas |
| United States | Center for Dermatology Clinical Research Inc. | Fremont | California |
| United States | Gulf Bank Medical Center | Houston | Texas |
| United States | Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana |
| United States | UCSD Perlman Medical Offices | La Jolla | California |
| United States | Reliant Medical Research | Miami | Florida |
| United States | Paramount Medical Research & Consulting, LLC | Middleburg Heights | Ohio |
| United States | Vanderbilt University Medical Center | Nashville | Tennessee |
| United States | Yale Center for Clinical Investigation (YCCI) | New Haven | Connecticut |
| United States | Columbia University Medical Center- Herbert Irving Pavilion | New York | New York |
| United States | HMD Research LLC | Orlando | Florida |
| United States | Dept. of Dermatology, Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (PCAM) | Philadelphia | Pennsylvania |
| United States | Epic Medical Research - Red Oak | Red Oak | Texas |
| United States | Sun Research Institute | San Antonio | Texas |
| United States | Inland Rheumatology Clinical Trials Inc. | Upland | California |
| Lead Sponsor | Collaborator |
|---|---|
| Gilead Sciences |
United States, Czechia, Germany, Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12 | The CLASI is a standardized, validated measure of cutaneous lupus disease activity and damage, widely used in clinical trials. CLASI consists of CLASI - activity (A) and - damage (D) measurements. CLASI-A scores range from 0 to 70, with higher scores indicating more severe disease activity. | Baseline, Week 12 | |
| Secondary | Proportion of Participants With Cutaneous Lupus Activity Investigator Global Assessment (CLA-IGA) Score of 0 or 1 at Week 12 | The CLA-IGA is a measure of cutaneous lupus erythematosus (CLE) activity and will be recorded on a scale of 0 to 4, with 0 indicating "clear" and 4 indicating "severe". | Week 12 | |
| Secondary | Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | First dose date up to 12 weeks plus 30 days | ||
| Secondary | Percentage of Participants Experiencing Serious Treatment-emergent Adverse Events (TESAEs) | First dose date up to 12 weeks plus 30 days | ||
| Secondary | Percentage of Participants Experiencing Laboratory Abnormalities | First dose date up to 12 weeks plus 30 days | ||
| Secondary | Plasma Concentration of Edecesertib | Postdose at Week 2, Predose at Week 4 and 12, and Week 8 (anytime of the day) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00633945 -
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
|
N/A | |
| Recruiting |
NCT05411016 -
A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
|
Phase 1 | |
| Recruiting |
NCT01510067 -
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
|